Literature DB >> 7537003

Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A.

M Warny1, C Denie, M Delmée, C Lefebvre.   

Abstract

A 53-year-old woman suffered six episodes of Clostridium difficile-pseudomembranous colitis. The serological follow-up demonstrated the absence of a rise in IgG and IgA to toxin A. Human pooled gamma globulin was administered during the fifth relapse and raised IgG levels to toxin A. Normal stools reappeared a week later. The role of the antibodies to toxin A and gamma globulin in C. difficile colitis are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537003     DOI: 10.1080/17843286.1995.11718419

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  11 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

3.  Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea.

Authors:  I L P Beales
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

4.  Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

Authors:  K L Kotloff; S S Wasserman; G A Losonsky; W Thomas; R Nichols; R Edelman; M Bridwell; T P Monath
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 5.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

6.  Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.

Authors:  A Qamar; S Aboudola; M Warny; P Michetti; C Pothoulakis; J T LaMont; C P Kelly
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 7.  Clostridium difficile infection in the intensive care unit.

Authors:  David J Riddle; Erik R Dubberke
Journal:  Infect Dis Clin North Am       Date:  2009-09       Impact factor: 5.982

8.  Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice.

Authors:  D Pavliakova; J S Moncrief; D M Lyerly; G Schiffman; D A Bryla; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

9.  Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.

Authors:  P J Giannasca; Z X Zhang; W D Lei; J A Boden; M A Giel; T P Monath; W D Thomas
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

10.  Recurrent C. difficile in a Patient with IgG Deficiency.

Authors:  Asad Jehangir; Kyle Bennett; Shoaib Bilal Fareedy; Andrew Rettew; Bilal Shaikh; Anam Qureshi; Qasim Jehangir; Richard Alweis
Journal:  Case Rep Gastrointest Med       Date:  2015-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.